H 89 2HCl: Potent PKA Inhibitor for cAMP/PKA Pathway Dissection

Executive Summary: H 89 2HCl is a potent and selective inhibitor of protein kinase A (PKA) with a Ki of 48 nM in cell-free assays, displaying approximately 10-fold selectivity over PKG and over 500-fold selectivity against other kinases such as PKC and MLCK (APExBIO). The compound modulates cAMP/PKA signaling without altering intracellular cAMP concentrations, enabling precise studies of cAMP-dependent protein phosphorylation. Cellular and animal models confirm that H 89 2HCl inhibits forskolin-induced neurite outgrowth and CREB-dependent transcription, providing a robust tool for dissecting signaling mechanisms (Wang et al., 2021). Its physicochemical properties and storage guidelines ensure reproducibility in research workflows. H 89 2HCl is an indispensable chemical probe for translational studies in neurodegeneration, bone biology, and oncology.

Biological Rationale

Protein kinase A (PKA) is a central node in the cAMP-dependent signaling pathway. It phosphorylates diverse substrates, including CREB (cAMP response element-binding protein), modulating gene expression and cellular phenotypes in neuronal, bone, and cancer biology (Wang et al., 2021). Dysregulation of cAMP/PKA signaling is implicated in neurodegenerative disease, aberrant bone remodeling, and tumorigenesis. Precise pharmacological modulation—through selective inhibitors such as H 89 2HCl—enables the interrogation of pathway dependencies and the identification of new therapeutic targets. The specificity and potency of H 89 2HCl make it a preferred tool for studies requiring accurate discrimination between PKA-mediated and alternative kinase-dependent processes.

Mechanism of Action of H 89 2HCl

H 89 2HCl, also known as (E)-N-(2-((3-(4-bromophenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide dihydrochloride, is a reversible ATP-competitive inhibitor of PKA catalytic subunits. It binds to the ATP-binding pocket of PKA, blocking substrate phosphorylation events downstream of cAMP activation (APExBIO). The compound does not reduce intracellular cAMP levels, as shown in PC12D pheochromocytoma cells, but selectively impairs cAMP-induced events such as neurite outgrowth and histone IIb phosphorylation. H 89 2HCl displays approximately 10-fold selectivity for PKA over PKG and over 500-fold selectivity versus non-cAMP-dependent kinases like PKC, MLCK, CaMKII, and casein kinase I/II. Off-target activity has been documented against S6K1, MSK1, ROCKII, PKBα, and MAPKAP-K1b, with IC₅₀ values ranging from 80 nM to 2800 nM, necessitating dose optimization for pathway-specific studies (Wang et al., 2021).

Evidence & Benchmarks

• H 89 2HCl has a Ki of 48 nM for PKA in cell-free kinase assays (APExBIO).
• Displays ∼10-fold selectivity for PKA over PKG and >500-fold selectivity versus PKC, MLCK, CaMKII, and casein kinase I/II (APExBIO).
• Inhibits S6K1, MSK1, ROCKII, PKBα, and MAPKAP-K1b with IC₅₀ values from 80 nM to 2800 nM, illustrating the importance of dose titration (Wang et al., 2021).
• Suppresses forskolin-induced neurite outgrowth in PC12D cells dose-dependently, without reducing cAMP levels (Wang et al., 2021).
• Reduces CREB phosphorylation during osteoclastogenesis in vitro, demonstrating pathway specificity in bone models (Wang et al., 2021).

For a deeper mechanistic perspective, see Strategic Interrogation of cAMP/PKA Signaling, which provides an experimental roadmap for H 89 2HCl deployment and expands on translational disease contexts. This article extends those analyses with updated selectivity and storage data.

Applications, Limits & Misconceptions

H 89 2HCl is widely used in research on:

• cAMP/PKA signaling modulation in neuronal differentiation, plasticity, and neurodegeneration.
• Bone remodeling, particularly in models of dopamine-regulated osteoclastogenesis (Wang et al., 2021).
• Oncology, for dissecting PKA-dependent proliferation and apoptosis mechanisms.
• Protein phosphorylation studies, enabling discrimination of PKA versus non-PKA effects.

See also H 89 2HCl: Advanced Insights into PKA Inhibition, which details translational research applications; the present article provides enhanced selectivity and solubility parameters.

Common Pitfalls or Misconceptions

• H 89 2HCl is not entirely specific to PKA; off-target inhibition occurs at higher concentrations (e.g., S6K1, PKBα).
• It does not reduce cAMP synthesis or levels; it acts downstream at the kinase level.
• Not suitable for clinical or diagnostic use; for research only (APExBIO).
• Insoluble in water and ethanol; only soluble at ≥51.9 mg/mL in DMSO.
• Solutions degrade over time; use promptly and store solid at -20°C.

For a comparison of inhibitor selectivity, see H 89 2HCl: Potent and Selective Protein Kinase A Inhibitor. This article updates solubility and off-target activity data.

Workflow Integration & Parameters

• Preparation: Dissolve H 89 2HCl in DMSO to a stock concentration of ≥51.9 mg/mL. Avoid water or ethanol as solvents due to insolubility.
• Storage: Store solid at -20°C. Prepare fresh working solutions for each experiment.
• Concentration: For PKA-specific inhibition, use at or near the Ki (48 nM) in cell-free systems; titrate higher for cellular models, monitoring off-target effects.
• Controls: Include DMSO-only controls and alternative kinase inhibitors to assess specificity.
• Readouts: Utilize phosphorylation assays (e.g., CREB, histone IIb) and phenotypic endpoints (e.g., neurite outgrowth, osteoclast differentiation).

For stepwise guidance on protocol integration, refer to Dissecting cAMP/PKA Signaling with H 89 2HCl, which provides experimental workflows; the current article offers updated benchmarking data and storage recommendations.

Conclusion & Outlook

H 89 2HCl, as supplied by APExBIO, remains a gold-standard probe for dissecting cAMP/PKA signaling in basic and translational research. Its well-characterized selectivity profile, robust biochemical benchmarks, and defined physicochemical properties enable reliable interrogation of kinase-dependent signaling in neurobiology, bone remodeling, and oncology. Continued optimization of usage parameters and benchmarking against emerging inhibitors will further enhance its research value. For product details and ordering information, see the H 89 2HCl product page.